

AETHLON MEDICAL INC  
Form 8-K  
June 03, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 3, 2016

**AETHLON MEDICAL, INC.**

(Exact name of registrant as specified in its charter)

|                              |                          |                        |
|------------------------------|--------------------------|------------------------|
| Nevada                       |                          | 13-3632859             |
| (State or other jurisdiction | 001-37487                | (IRS Employer          |
| of incorporation)            | (Commission File Number) | Identification Number) |

9635 Granite Ridge Drive, Suite 100  
San Diego, California 92123  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (858) 459-7800

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## FORWARD-LOOKING STATEMENTS

This Form 8-K and other reports filed by the registrant from time to time with the Securities and Exchange Commission (collectively, the "Filings") contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the registrant's management as well as estimates and assumptions made by the registrant's management. When used in the Filings the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan" or the negative of these terms and similar expressions as they relate to the registrant or the registrant's management identify forward-looking statements. Such statements reflect the current view of the registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the registrant's industry, the registrant's operations and results of operations and any businesses that may be acquired by the registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Although the registrant believes that the expectations reflected in the forward-looking statements are reasonable, the registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.

## ITEM 7.01 REGULATION FD DISCLOSURE.

Today, June 3, 2016, Mr. James Joyce, Chief Executive Officer of Aethlon Medical, Inc. (the "Company"), presented at the 2nd Annual Sachs Associates Immuno-oncology: BD&L and Investment Forum. A link to the presentation may be accessed on the Company's website under the investor relations section of the website. The website address is [www.aethlonmedical.com](http://www.aethlonmedical.com). No portion of the website shall be deemed to be incorporated into this Current Report on Form 8-K.

## ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. (d) EXHIBITS

| EXHIBIT NO. | DESCRIPTION |
|-------------|-------------|
|-------------|-------------|

|      |  |
|------|--|
| 99.1 | Presentation materials – 2nd Annual Sachs Associates Immuno-oncology: BD&L and Investment Forum – June 3, 2016 |
|------|--|



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC.

By: /s/ James B. Frakes

James B. Frakes

Dated: June 3, 2016 Chief Financial Officer



**EXHIBIT INDEX**

| EXHIBIT<br>NO. | DESCRIPTION  |
|----------------|--|
| 99.1           | Presentation materials – 2nd Annual Sachs Associates Immuno-oncology: BD&L and Investment Forum – June 3, 2016 |